DESCRIPTION (provided by applicant):
Selective tumor delivery of therapeutic genes is instrumental to the success of numerous cancer gene therapy protocols. The objective of this research proposal, which is a key step in our long-term goal to develop safe and efficient vectors for systemic human cancer gene therapy, is to prepare polyplexes capable of selective surface presentation of targeting ligands in response to small physiologically relevant decrease of pH. Well defined, end-functionalized copolymers of N-isopropylacrylamide and 1-vinylimidazole, which display pH-induced globule-to-coil phase transition at body temperature, will be synthesized by RAFT polymerization, conjugated with PEG, protamine, and targeting ligands, and used to prepare polyplexes with plasmid DNA and oligonucleotides. We hypothesize that pH-triggered phase transition will display targeting ligands selectively at slightly acidic pH and permit pH-selective cellular uptake. The phase state-controlled tropism of polyplexes will be investigated by analyzing pH-dependent binding of biotin-containing polyplexes to immobilized avidin and by measuring the levels of pH-dependent cellular uptake of non-specifically-binding and integrin- and asialoglycoprotein-binding polyplexes in cell culture. To our knowledge, this is the first use of stimuli-responsive polymers to control tropism of synthetic self-assembly vectors for gene delivery. While preliminary results demonstrating the feasibility of controlling surface properties of polyplexes by the phase state of the stimulus-responsive copolymers are presented, the modulation of ligand binding by pH needs to be clearly demonstrated to establish the feasibility of this approach. Funding through the NIBIB R21 mechanism will allow us to test the validity of our hypothesis and establish a design platform for further development of polyplexes with stimuli-responsive tropism. The polyplexes with pH-controlled tropism, proposed here, will be exploited in the development of gene delivery vectors that recognize and selectively display targeting ligands in slightly acidic extracellular pH of many solid tumors; thus minimizing the need for tumor-specific ligands.
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
001962224
UEI
M6K6NTJ2MNE5
Project Start Date
01-January-2005
Project End Date
30-September-2007
Budget Start Date
01-January-2006
Budget End Date
30-September-2007
Project Funding Information for 2006
Total Funding
$180,082
Direct Costs
$122,063
Indirect Costs
$58,019
Year
Funding IC
FY Total Cost by IC
2006
National Institute of Biomedical Imaging and Bioengineering
$180,082
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R21EB004388-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R21EB004388-02
Patents
No Patents information available for 5R21EB004388-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R21EB004388-02
Clinical Studies
No Clinical Studies information available for 5R21EB004388-02
News and More
Related News Releases
No news release information available for 5R21EB004388-02
History
No Historical information available for 5R21EB004388-02
Similar Projects
No Similar Projects information available for 5R21EB004388-02